BACKGROUND: Fetuin-A is a circulating inhibitor of ectopic calcification. Low plasma levels have been associated in some studies with increased vascular calcification, aortic stiffness and mortality in patients with Chronic Kidney Disease (CKD). However, there are other studies examining the association of fetuin-A with vascular parameters and mortality, which do not show these associations. These conflicting data may be explained by methodological differences. METHODS: We compared plasma fetuin-A measurements made with two widely-used commercial fetuin-A ELISA kits (Biovendor, Modrice, Czech Republic; Epitope Diagnostics Inc., San Diego, US) in samples from patients with and without CKD. We evaluated the effect of differences in fetuin-A glycosylation status on assay specificity. RESULTS: Deming regression analysis showed poor agreement between methods (for CKD cohort: y=-0.05+2.52x, S(y|x)=0.099g/L, R(2)=0.694). The Epitope Diagnostics kit demonstrated significant positive bias and greater specificity for deglycosylated fetuin-A relative to the Biovendor assay. CONCLUSION: The apparently contradictory nature of reports of the association of fetuin-A with biological variables may reflect differences in the specificity of different ELISA methods for glycosylated plasma fetuin-A. Copyright 2010 Elsevier B.V. All rights reserved.
BACKGROUND:Fetuin-A is a circulating inhibitor of ectopic calcification. Low plasma levels have been associated in some studies with increased vascular calcification, aortic stiffness and mortality in patients with Chronic Kidney Disease (CKD). However, there are other studies examining the association of fetuin-A with vascular parameters and mortality, which do not show these associations. These conflicting data may be explained by methodological differences. METHODS: We compared plasma fetuin-A measurements made with two widely-used commercial fetuin-A ELISA kits (Biovendor, Modrice, Czech Republic; Epitope Diagnostics Inc., San Diego, US) in samples from patients with and without CKD. We evaluated the effect of differences in fetuin-A glycosylation status on assay specificity. RESULTS: Deming regression analysis showed poor agreement between methods (for CKD cohort: y=-0.05+2.52x, S(y|x)=0.099g/L, R(2)=0.694). The Epitope Diagnostics kit demonstrated significant positive bias and greater specificity for deglycosylated fetuin-A relative to the Biovendor assay. CONCLUSION: The apparently contradictory nature of reports of the association of fetuin-A with biological variables may reflect differences in the specificity of different ELISA methods for glycosylated plasma fetuin-A. Copyright 2010 Elsevier B.V. All rights reserved.
Authors: Julia J Scialla; W H Linda Kao; Ciprian Crainiceanu; Stephen M Sozio; Pooja C Oberai; Tariq Shafi; Josef Coresh; Neil R Powe; Laura C Plantinga; Bernard G Jaar; Rulan S Parekh Journal: Clin J Am Soc Nephrol Date: 2014-01-23 Impact factor: 8.237
Authors: Sarah A Aroner; Kenneth J Mukamal; David E St-Jules; Matthew J Budoff; Ronit Katz; Michael H Criqui; Matthew A Allison; Ian H de Boer; David S Siscovick; Joachim H Ix; Majken K Jensen Journal: Am J Epidemiol Date: 2016-11-17 Impact factor: 4.897
Authors: F Roshanzamir; M Miraghajani; M H Rouhani; M Mansourian; R Ghiasvand; S M Safavi Journal: J Endocrinol Invest Date: 2017-06-22 Impact factor: 4.256
Authors: Marta Díaz; José Miguel Gallego-Escuredo; Abel López-Bermejo; Francis de Zegher; Francesc Villarroya; Lourdes Ibáñez Journal: Int J Endocrinol Date: 2018-07-19 Impact factor: 3.257
Authors: Majken K Jensen; Traci M Bartz; Kenneth J Mukamal; Luc Djoussé; Jorge R Kizer; Russell P Tracy; Susan J Zieman; Eric B Rimm; David S Siscovick; Michael Shlipak; Joachim H Ix Journal: Diabetes Care Date: 2012-12-18 Impact factor: 19.112
Authors: Qi Sun; Monik C Jiménez; Mary K Townsend; Eric B Rimm; JoAnn E Manson; Christine M Albert; Kathryn M Rexrode Journal: J Am Heart Assoc Date: 2014-06-24 Impact factor: 5.501